TransAlgae Overview
TransAlgae develops an algae-based platform for the oral delivery of drugs (vaccines, immune modulators, insecticides, etc.) for human and animal health and for crop protection. TransAlgae's drug-delivery platform was demonstrated on mice as a model for humans. TransAlgae successfully demonstrated that proteins, expressed in algae, were orally delivered to the mice blood and liver in their intact form, due to the native bio-encapsulation of the algae and the formulation that TransAlgae has developed. In the area of animal health, TransAlgae's oral-delivery technology replaces the need for antibiotics and vaccination by injections. The company's algal powder, containing the desired drug or vaccine, is used as a feed supplement, enabling vaccination by feeding. TransAlgae has also developed a proprietary platform for the delivery of biological-based insecticides to be sprayed on crops. The technology enables targeting particular insects in a specific manner, replacing the need for toxic chemicals. The genetically modified algae are inactive, thus not affecting humans, animals, or crops, and are classified as a GMO-derived material.
Cumulative Funding Raised Over Time ($)
$3.0M
$5.5MApr 2021
$15.5MMar 2016
$27.5MMay 2008
Latest News
growth-positive
TransAlgae Raises Additional $2.5M For Algae-Based Oral Vaccine Solution
Israeli biotech firm TransAlgae has raised an additional $2.5 million in an investment round led by Gan Shmuel Foods. This investment adds to the $10.56 million previously invested by Gan Shmuel Foods. TransAlgae is currently in the midst of a $27 million fundraising round led by KPMG. The company has developed a breakthrough technology using genetically engineered algae for oral drug delivery in human pharmaceuticals, animal health, and crop protection. The technology has shown promising results in mice, where orally delivered proteins triggered the appearance of antibodies. TransAlgaes oral-delivery technology also has applications in animal health and the development of bioinsecticides for crops using RNA interference.
Investment
growth-positive
Microalgae biotech startup raises additional $2.5 million
Israeli microalgae producer, TransAlgae, has secured $2.5 million in funding from Gan Shmuel Foods. TransAlgae has previously developed oral vaccines and is currently in a fundraising round for $27 million. The companys patented algae-based oral delivery technology is used in aquaculture and the development of bioinsecticides.
Investment
growth-positive
TransAlgae's Oral Vaccination Solution for Wildlife and Farm Animals Challenges
TransAlgae has signed an exclusive business development collaboration agreement with Virbac, a leading animal health company. The agreement aims to develop a vaccine based on TransAlgaes microalgae-based oral delivery technology. This collaboration is expected to revolutionize the world of vaccination by providing an effective and industrialized method. TransAlgaes technology utilizes microalgae as a production site and delivery vehicle for therapeutic drugs. The agreement with Virbac is a vote of confidence in TransAlgaes technology and will benefit the animal cultivation industry.
Partners
growth-positive
TransAlgae and Virbac to develop an algae-based oral delivery vaccine Food and Farming Technology
Israeli biotech company TransAlgae has signed an exclusive agreement with French company Virbac to develop its microalgae-based oral delivery vaccine technology. The partnership aims to revolutionize the world of vaccination by providing an effective and industrialized method. TransAlgaes technology uses genetically engineered algae to orally deliver therapeutic drugs, such as vaccines, for human pharma, animal health, and crop protection. The collaboration with Virbac is a vote of confidence in TransAlgaes technology and will benefit the animal cultivation industry. The partnership will eliminate unnecessary labor and loss of animal life, reduce costs and time consumption, and improve the quality of life for animals.
Partners
growth-positive
Microalgae deliver animal vaccines orally;Covid next?
TransAlgae, an Israeli biotech startup, has developed a technology to deliver vaccines orally to animals using genetically engineered microalgae. The company recently signed a collaboration agreement with Virbac, a global animal health company, to create an industrialized vaccination method and manufacturing site. TransAlgaes technology can also be used as an alternative to chemical crop insecticide sprays. The company has invested $25 million in developing its technology and is seeking additional capital, particularly for its proposed oral Covid-19 vaccine for humans. The powdered algae vaccine is currently being tested against diseases in fish, shrimp, and swine.
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $29.52M |
| Last funding | $2.5M |
| Stage | A |
| Rounds | 6 |
| Investors | 2 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | www.transalgae.com |
| Careers | Careers page |
Locations
Prof. Haim Pekeris St 2, Rehovot, Israel
Photos & Videos
No files yet
TransAlgae Business
Business models
B2C, B2B
Product stage
Released
Employees
11-50
Sector
Climate TechFood & Land UseSustainable FarmingHealth Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryTarget Customer
Agriculture & FoodCropsMarine LifeSea FoodFishLivestockHealthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsCellsTags (12)
veterinaryalgaebiotechnologyagtechlivestockclimate-techpest-controldrug-deliveryplant-protectionanimal-healthpharmaceuticalsvaccinesGeographic Markets
GlobalTransAlgae Financials
$29.52M
Total funding
Undisclosed
Capital raised
$2.5M
Last funding
A
Funding stage
6
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$3.0M
$5.5MApr 2021
$15.5MMar 2016
$27.5MMay 2008
Private Equity Funding
Undisclosed Round
Apr 2021
$2.5M
Gan Shmuel
Convertible Debt
Mar 2016
$10M
Gan Shmuel
A Round
May 2008
$12M
Undisclosed Investor(s)
Undisclosed Round
$3M
Non-Equity Funding
GrantEvent
Nov 2017
$519.75K
EU Horizon 2020
GrantEvent
$1.5M
Israel Innovation Authority
TransAlgae Lifecycle
Cumulative Funding Raised Over Time
$3.0M
$5.5MApr 2021
$15.5MMar 2016
$27.5MMay 2008
All Events
Undisclosed Round
Apr 2021
$2.5M
Gan Shmuel
Convertible Debt
Mar 2016
$10M
Gan Shmuel
A Round
May 2008
$12M
Undisclosed Investor(s)
Undisclosed Round
$3M
GrantEvent
Nov 2017
$519.75K
EU Horizon 2020
GrantEvent
$1.5M
Israel Innovation Authority
TransAlgae News
10 articles
growth-positive
TransAlgae Raises Additional $2.5M For Algae-Based Oral Vaccine Solution
Israeli biotech firm TransAlgae has raised an additional $2.5 million in an investment round led by Gan Shmuel Foods. This investment adds to the $10.56 million previously invested by Gan Shmuel Foods. TransAlgae is currently in the midst of a $27 million fundraising round led by KPMG. The company has developed a breakthrough technology using genetically engineered algae for oral drug delivery in human pharmaceuticals, animal health, and crop protection. The technology has shown promising results in mice, where orally delivered proteins triggered the appearance of antibodies. TransAlgaes oral-delivery technology also has applications in animal health and the development of bioinsecticides for crops using RNA interference.
Investment
growth-positive
Microalgae biotech startup raises additional $2.5 million
Israeli microalgae producer, TransAlgae, has secured $2.5 million in funding from Gan Shmuel Foods. TransAlgae has previously developed oral vaccines and is currently in a fundraising round for $27 million. The companys patented algae-based oral delivery technology is used in aquaculture and the development of bioinsecticides.
Investment
growth-positive
TransAlgae's Oral Vaccination Solution for Wildlife and Farm Animals Challenges
TransAlgae has signed an exclusive business development collaboration agreement with Virbac, a leading animal health company. The agreement aims to develop a vaccine based on TransAlgaes microalgae-based oral delivery technology. This collaboration is expected to revolutionize the world of vaccination by providing an effective and industrialized method. TransAlgaes technology utilizes microalgae as a production site and delivery vehicle for therapeutic drugs. The agreement with Virbac is a vote of confidence in TransAlgaes technology and will benefit the animal cultivation industry.
Partners
growth-positive
TransAlgae and Virbac to develop an algae-based oral delivery vaccine Food and Farming Technology
Israeli biotech company TransAlgae has signed an exclusive agreement with French company Virbac to develop its microalgae-based oral delivery vaccine technology. The partnership aims to revolutionize the world of vaccination by providing an effective and industrialized method. TransAlgaes technology uses genetically engineered algae to orally deliver therapeutic drugs, such as vaccines, for human pharma, animal health, and crop protection. The collaboration with Virbac is a vote of confidence in TransAlgaes technology and will benefit the animal cultivation industry. The partnership will eliminate unnecessary labor and loss of animal life, reduce costs and time consumption, and improve the quality of life for animals.
Partners
growth-positive
Microalgae deliver animal vaccines orally;Covid next?
TransAlgae, an Israeli biotech startup, has developed a technology to deliver vaccines orally to animals using genetically engineered microalgae. The company recently signed a collaboration agreement with Virbac, a global animal health company, to create an industrialized vaccination method and manufacturing site. TransAlgaes technology can also be used as an alternative to chemical crop insecticide sprays. The company has invested $25 million in developing its technology and is seeking additional capital, particularly for its proposed oral Covid-19 vaccine for humans. The powdered algae vaccine is currently being tested against diseases in fish, shrimp, and swine.
PartnersInvestment
growth-positive
6 coronavirus vaccine developments from Israel to watch
The article discusses various vaccine candidates being developed in Israeli labs, including MigVax, a startup spun out of Migal Galilee Research Institute. MigVax is developing an oral human vaccine against Covid-19 using methods from their poultry vaccine program. The vaccine is a sub-unit vaccine that contains pieces of coronavirus protein delivered orally to stimulate the immune system. MigVax recently received a $12 million funding round from OurCrowd. The article also mentions other Israeli labs, such as the Israel Institute of Biological Research and TransAlgae, that are working on Covid-19 vaccine candidates. Israeli academic labs are also contributing to vaccine research. The article does not mention any specific customers or the valuation or acquisition amounts. The date of the event described in the article is not provided.
Investment
growth-positive
Showcase shortlist: meet the innovators - TransAlgae
TransAlgae, an Israeli biotechnology firm, has developed a microalgae-based platform that delivers pharmaceuticals, growth promoting agents, immuno-modulators, and vaccines via fish feed. The companys technology is cost-effective, environmentally friendly, and reduces labor-intensive farm tasks. TransAlgaes focus on delivering pharmaceuticals that wont leave environmental remnants sets it apart from competitors. Recent trials of their algae platform have been successful, and the company will be featured in the Aquaculture Innovation Showcase. TransAlgaes technology can be adapted to freshwater fish, marine fish, crustaceans, poultry, and swine sectors. The company is seeking strategic partners and aims to expand its portfolio with the technology.
PartnersCustomers
growth-positive
New oral vaccine for farmed fish can be put in feed
Scientists at Temasek Polytechnic are working with an Israeli partner to develop an easier process for vaccinating fish. They have developed an oral vaccine against fish iridovirus by inserting parts of the virus into a special type of microalgae, which is then mixed with fish feed. The key to developing the oral vaccine was finding a substance that could protect the biological compounds from being destroyed by fish stomach acids. The hope is that this new method will encourage wider adoption of fish vaccination, reducing the need for antibiotics and leading to healthier fish. The oral vaccine is expected to be rolled out commercially by 2021.
Customers
growth-positive
Is 2016 the year of algae?
The article discusses the potential of algae as a solution to various problems facing mankind. It highlights the significant investment in algae-based technologies, with Israel being at the forefront of innovation in this field. The article mentions eight Israeli companies that are betting on algae for growth and development. These companies are involved in various applications of algae, including renewable fuel, animal feed, cosmetics, and food products. The impact of the article on the companies is growth-positive, as it highlights the potential and opportunities in the algae industry. The key theme of the article is the use of algae for various purposes. The key issues discussed in the article are investment and expansion. The article does not mention specific investors or acquirers. The date of the event described in the article is not provided. My confidence in the answer is 8/10.
InvestmentExpand
TransAlgae Seeds A Need For Green Feed - Green Prophet
TransAlgae Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 12 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 17 classification IDs that could be used for matching.
TransAlgae Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | video or image, markets |
| BI Verification | Yamila Silbert |
| Registrar ID | 514134550 |
| Crunchbase | transalgae |
| Phone | +97289366167 |
| Last updater | Roxanne Sluszny |
| Updater email | roxanne.sluszny@sncentral.org |
| Last update | 2021-04-25T00:00:00.000Z |
| Created | 2014-11-24T00:00:00.000Z |
| Claimed | Yes |